Introduction
============

Register-based data on drug use are increasingly utilized in various research questions.[@b1-clep-8-363] Interview-based drug use assessment is time-consuming and collection of such data may lead to a significant cost. Register-based drug data provide an alternative source of drug use information. Register-based purchase data are extensive and provide large and representative samples of the population. Drug utilization and associated beneficial and adverse outcomes may be accurately deduced from register-based data sources. On the contrary, interview-based drug exposure represents assessment of current drug use, and it cannot consider changes during long time periods. In addition, interview data are dependent on the actual way that drug use is questioned and is subject to recall bias.

Validity of Finnish Prescription register to describe psychotropic drug use has been previously demonstrated.[@b2-clep-8-363] Rikala et al compared self-reported drug use information collected in annual interviews to drugs purchased by the participants according to Prescription register data in Finland. They assessed which time windows captured self-reported drug use in the register data correctly. This validation study showed that register-based data are a valid source for psychotropic drug use among older persons and that reimbursement status of drugs had an impact on the sensitivity and specificity measures. Similar results were also reported by Haukka et al[@b3-clep-8-363] on psychotropic drug use by persons with schizophrenia.

Previous studies have determined the agreement between pharmacy records and drug use reported in the interview or home inventory of drugs to be mostly moderate or good.[@b2-clep-8-363],[@b4-clep-8-363]--[@b8-clep-8-363] The comprehensiveness of the interview varied from survey to patient interview and to home drug inventory between the studies. Methods used for dispensing data varied between time windows (30, 60, or 90 days, or 4, 6, or 12 months), legend duration method assuming that duration for dispensing was the purchased amount divided by one defined daily dose per day (with or without any allowance for lower than perfect adherence) or divided by the prescribed dose and dispensing during the past 6 months for at least three times and at least once in the past month.

In this study, PRE2DUP method that models drug use longitudinally and assigns times when drug was used and when it was not used according to the regularity of drug purchases in pharmacy records was applied.[@b9-clep-8-363] PRE2DUP is a data-driven method that generates drug use periods from drug purchases recorded in register-based data. The method evaluates personal drug purchasing patterns in order to calculate an estimate of how long each drug purchase will last with the local estimated dosage and regularity of purchases. It considers hospital stays, possible stockpiling of drugs, and package information designed to control joining of the purchases. The method utilizes drug use pattern of the drug and package in the study population to determine the duration for single purchases. It uses recursive recalculation of the model and can be guided to more accurate results by adjusting drug-specific parameters. Validity of the PRE2DUP method was previously investigated by expert opinion-based evaluation on whether drug purchases recorded in the dispensing data were correctly placed in drug use periods and which purchases formed a continuous drug use period. The correctness of purchases included in the drug use period defined whether the duration of use was correctly estimated.

The objective of our study was to validate PRE2DUP method against interview-reported drug use data for various drug classes used by older persons. The agreement between interview and PRE2DUP-modeled data was tested in person level and considering discrepancies in both the data sources.

Materials and methods
=====================

The Geriatric Multidisciplinary Strategy for the Good Care of the Elderly (GeMS) Study was a randomized comparative study among persons aged ≥75 years.[@b10-clep-8-363]--[@b13-clep-8-363] The study evaluated a model for geriatric assessment, care, and rehabilitation. A random sample of inhabitants of the city of Kuopio, Finland, were invited to participate and were randomized to intervention (N=500) and comparison (N=500) groups. Originally of these 1000 people, 781 provided written informed consent to participate, 162 refused participation, 2 relocated, and 55 died before the baseline examination. Altogether, 700 community-dwelling participants were included in the study at the baseline. The baseline examination was conducted in 2004, and annual examinations were conducted until 2007. The study was approved by the Research Ethics Committee of the Northern Savo Hospital District, Kuopio, Finland.

All the participants attended an interview in which their drug use, together with health status, and sociodemographic factors were thoroughly assessed by a trained nurse. Participants in both the groups continued to receive usual care during the study period. Participants' self-reported drug use and diagnoses were verified from medical records from municipal health centers, home nursing service, local hospitals, and the Kuopio University Hospital. Drug use was thoroughly assessed, and the participants were also asked to bring their prescription forms and drug packages to the interview. If a participant had a prescription form, drug package, or medical record that suggested they took a drug that they did not self-report, then the nurse interviewer specifically asked about the use of this drug over the previous 2 weeks. Drug use was assessed on the basis of each participant's actual pattern of use rather than the clinician's prescribed or intended pattern of use. Drug use was also categorized as regular or as required use and was categorized according to Anatomical Therapeutic Chemical (ATC) coding system.[@b14-clep-8-363] Regularity of drug use was determined for each participant and drug according to their self-reported drug use by asking whether the drug is used regularly or on "as needed" basis and how often "as needed" drugs were actually used during the previous 2 weeks.

Data on drug purchases for the GeMS Study participants 2002--2007 were retrieved from Prescription register, which includes all reimbursed and prescribed drugs dispensed from pharmacies. Prescription register data are restricted to community-dwelling persons as drugs used in long-term care facilities are provided by the institution. When drug use started and ended, drug use periods were modeled from drug purchases with a PRE2DUP method.[@b9-clep-8-363] The modeling is based on sliding averages of daily dose (in defined daily doses)[@b15-clep-8-363] and was conducted separately with each ATC code for each person. The modeling aims to describe the actual pattern of use based on purchase regularity and considers hospitalizations, stockpiling of drugs, and changing dose. The method is described in more detail and drug use periods produced by PRE2DUP are validated against expert opinion by Tanskanen et al.[@b9-clep-8-363] As drug use in the interview was assessed as drugs used during previous 2 weeks, which drug use periods produced by PRE2DUP were ongoing during a 2-week period preceding the interview date ([Figure 1](#f1-clep-8-363){ref-type="fig"}) was assessed. Drug use periods might be ongoing the whole period or a part of it.

We compared self-reported and register-based data in several commonly used drugs or drug classes among the study participants. Drugs were also chosen on the basis of reimbursement status during the study period as our objective was to assess the validity of drug use periods produced by PRE2DUP and not the coverage of the Prescription register. Hence, whether drug use periods modeled with PRE2DUP were ongoing at the time of the interview for drugs that were reimbursed in 2006 were compared. Validation year 2006 was chosen as fixed co-payment was removed from reimbursement regulations at the beginning of 2006, and thus, register data from earlier years are less valid for inexpensive drugs. Drug classes with at least 10 users (reported in interview) were included; however drugs used mainly over the counter (OTC; antihistamines, laxatives, and vitamins) and on short courses (antibiotics) were excluded. [Figure 2](#f2-clep-8-363){ref-type="fig"} describes the exclusion process for the selection of drugs or drug groups included in this study.

Benzodiazepines and related drugs (BZDRs) were defined to include both benzodiazepines (BZDs, ATC codes N05BA and N05CD) and benzodiazepine-related, so-called Z-drugs (ATC code N05CF). Triazolam and midazolam were excluded from BZDs because of their lack of reimbursement status. Codeine combinations (N02AA59) from opioids and acetylsalisylic acid (B01AC06) from antithrombotics were also excluded because they were not reimbursed in 2006. Glucosamine (M01AX05) was excluded from nonsteroidal anti-inflammatory drugs (NSAIDs).

In this study, community-dwelling persons were included and were interviewed in 2006, that is, alive and participated (loss of follow-up for the GeMS Study has been described elsewhere).[@b11-clep-8-363] Of 588 community-dwelling persons, 19 were excluded as their drug purchases were not recorded in the Prescription register data (indicative of living in long-term care facility providing drugs). After these exclusions, our study sample consisted of 569 persons.

Participants' self-reported diagnoses were complemented with data obtained from the Finnish Special Reimbursement Registers, including cardiovascular diseases, diabetes, and history of stroke. Functional comorbidity index was calculated according to Groll et al[@b16-clep-8-363] and as in a previous study.[@b12-clep-8-363] Dementia was diagnosed as Alzheimer's disease, vascular dementia or dementia due to other general medical conditions according to the *Diagnostic and Statistical Manual for Mental Disorders (DSM)-IV* criteria, and dementia with Lewy bodies according to the core criteria published by McKeith et al.[@b17-clep-8-363] Performance in Instrumental Activities of Daily Living was assessed using the eight-item scale developed by Lawton and Brody[@b18-clep-8-363] and was categorized as impaired Instrumental Activities of Daily Living (score 0--6) and normal function (score 7--8). Frailty was defined as frail, pre-frail, and robust as previously described.[@b19-clep-8-363] Mini-Mental State Examination[@b20-clep-8-363] was conducted by a trained nurse, and scores \<25 were categorized as indicative of cognitive impairment.

Statistical analyses
--------------------

Which drug use periods modeled by PRE2DUP method were ongoing during a 2-week period preceding the interview date were assessed. Agreement was tested in person level and in two different ways: 1) with self-reported drug use reported in the interview as a standard, which drugs were used by the participants according to register-based modeling were assessed, and 2) with drug use periods as a standard, whether drugs used according to register-based data were reported in the interview was assessed. The two-way agreement was tested because previous studies have indicated that also older persons under-report their drug use in interviews.[@b8-clep-8-363] This was conducted separately for all regular and "as needed" drugs together and separately for only regularly used drugs according to interview. Cohen's kappa statistics were calculated by considering the differences in both ways. Interpretation of the kappa value was as previously suggested: poor (\<0.20), fair (0.20--0.40), moderate (0.41--0.60), good (0.61--0.80), and very good (0.81--1.00).[@b21-clep-8-363]

Results
=======

Participants included in the study in 2006 were with a mean age of 82 years and 69% were women ([Table 1](#t1-clep-8-363){ref-type="table"}). About half of the study population was pre-frail and 15% were frail, whereas dementia was diagnosed in 17% of the participants. The participants frequently used drugs and almost one-third of them used 10 or more drugs.

Agreement between interview and register data modeled with PRE2DUP was very good for 75% and very good or good for 93% of the studied drugs or drug classes ([Table 2](#t2-clep-8-363){ref-type="table"}). Agreement was moderate for NSAIDs and poor for paracetamol.

While considering drugs reported to be used regularly in the interview, agreement between the interview and register data modeled with PRE2DUP was very good for 79% and very good or good for 89% of drug classes ([Table 3](#t3-clep-8-363){ref-type="table"}). Moderate agreement was observed for regular opioid use and fair agreement for NSAIDs and paracetamol. Interview as standard showed higher agreement for many drugs or drug classes than results when register-based drug use was considered as a standard.

Discussion
==========

This is the first study to compare the validity of PRE2DUP with self-reported drug use as previous validations of the method have been expert opinion-based evaluation on the duration of drug use periods.[@b9-clep-8-363] The agreement between PRE2DUP and drug use reported on a particular day represent finer level agreement. The correctness of drug exposure status is especially important while assessing the impact of drug use on the beneficial or adverse outcomes. Misclassification of exposure status would lead to biased risk estimates.

Overall agreement
-----------------

We found high agreement between self-reported drug use and drug use modeled with PRE2DUP method for the interview date. Agreement was very good or good for 93% of drugs and drug classes investigated while considering all drug use and 89% for regular drug use only. In this validation, 4 years of drug use history before the interview and 1 year after were examined, and hence, the estimates of current drug use were accurate. Data on drug purchases were also used, and hence, primary nonadherence problem found in data utilizing prescribed drugs was avoided. Using data on prescribed drugs instead of purchases could increase the number of users in the register-based results compared with the interview because drugs that have never been dispensed would appear in register data.

Comparison with previous studies
--------------------------------

Kappa values describing agreement between interview and modeled register data in our study were high compared with previous studies that have compared interview or survey data with register-based data modeled with various methods.[@b4-clep-8-363],[@b6-clep-8-363]--[@b8-clep-8-363] Only agreement in NSAIDs showed higher agreement in a previous study of French prescription data.[@b7-clep-8-363] For other comparable drug classes, our kappa values were similar (cardiovascular and respiratory drugs) or higher. Higher agreement in our study was found for antidiabetics (kappa values in previous studies were from 0.75 to 0.93, our study 0.98), lipid lowering drugs (previous studies from 0.73 to 0.85, our study 0.95), antipsychotics (previous studies from 0.54 to 0.76, our study 0.90), and drugs for the treatment of bone diseases (previous studies from 0.67 to 0.73, our study 0.90). All comparable drug classes in the results of Nielsen et al[@b6-clep-8-363] and Richardson et al[@b8-clep-8-363] showed poorer agreement between the data sources than our study.

OTC and "as needed" use
-----------------------

NSAIDs and paracetamol showed fairly poor agreement between PRE2DUP modeling and interview. This is because of several reasons. First, not all packages are reimbursed and smaller packages are available OTC. Second, these drugs are often used on "as needed" bases, that is, for symptomatic treatment. In the GeMS Study, the participants were not asked whether their drugs were prescribed by physician or bought OTC. To recall analgesic use during previous 2 weeks may be difficult without a diary especially for older people with several ongoing drug therapies. These factors may explain the under-reporting both from register and interview as standard. Poor agreement for "as needed" drugs has been found in previous studies comparing drug use between interview and dispensing data.[@b7-clep-8-363],[@b8-clep-8-363] Compared with the study by Noize et al,[@b7-clep-8-363] also the short time interval between purchases in France (1 month) compared with the Finnish dispensing regulations (3 months) makes modeling of many drug classes easier as dispensing intervals are shorter and better describe current use. The proportion of reimbursed NSAIDs in France may be larger than that in Finland,[@b22-clep-8-363] and the prevalence of OTC drug use may vary depending on the study population, age distribution, and accessibility of health care services. For analgesics, the actual timing of drug use is challenging to determine from register-based data with any method. Most likely the drug is used around the purchase date but the duration of use is somewhat speculative.

Agreement was less than very good also for BZDRs for which some smaller packages are not reimbursed. Furthermore, BZDRs should be used on "as needed" basis. The poorer agreement has been reported for benzodiazepines in previous studies.[@b6-clep-8-363]--[@b8-clep-8-363] "As needed" use is challenging to model from register-based data, which does not indicate whether drug use is intended for regular or "as needed" use, and for drugs with addictive potential, even intention of use is different from actual use. It should be noted that in our study, "regular use" was recorded only in the interview, whereas register-based data includes all purchased drugs. Thus, register data also cover some purchases of "as needed" drugs compared to the interview, and this decreases kappa values for regular use. The lower agreement between register-based and interview-based BZDR use has also been reported in previous Finnish studies.[@b2-clep-8-363],[@b3-clep-8-363] The recommended use of these drugs is short-term and only "as needed."[@b23-clep-8-363]

Drugs in chronic use
--------------------

High agreement was found in drugs that are used with fixed drug use patterns, such as statins, and drugs that are monitored, and doses are adjusted personally over the time such as antidiabetics. The higher agreement between interview and dispensing data for drugs used in the treatment of chronic diseases, such as cardiovascular diseases and diabetes, has been reported in all previous studies.[@b4-clep-8-363]--[@b8-clep-8-363]

Interview as golden standard
----------------------------

Although interview is often defined as golden standard for measuring drug use, it may also include some bias. In addition to unwillingness to report the use of particular drugs in the interview suggested in a previous study,[@b8-clep-8-363] the interviews, especially annual and repetitive interviews, may also pose changes in drug use behavior. When interview date is approaching, drugs and prescriptions are collected to recall drug use, and it is possible that this will lead to increased intensity of drug purchases. The interview itself may lead to re-starting of drug use that has been recently discontinued or forgotten for some time, especially in our study where data from the third repetitive interview was assessed and half of the group received a multidimensional health-related intervention which may have led to somewhat better adherence to drug therapy. Thus, even without an actual intervention such as medication review, an interview may pose an "intervention effect." This may lead to overestimation of drug use compared with randomly selected time. However, when register data are used as a standard, it also includes drugs that are not actually used or have been recently discontinued. These drugs lower the kappa values when discrepancies are recorded in both ways (interview and register as standard).

Comparison to previous methods and implications for future
----------------------------------------------------------

Our results are in line with results from previous studies on agreement between interview and dispensing data although methods used for dispensing data vary significantly between the studies.[@b2-clep-8-363],[@b4-clep-8-363]--[@b8-clep-8-363] For some specific drug classes, our kappa statistics show better agreement (eg, antipsychotics), which may also be related to different drug use patterns (ie, regular versus "as needed" use) between the study populations. The main difference between time window methods and all other methods based on the particular date of drug use is assessed, and PRE2DUP is continuity of drug use. For cohort studies following up persons in time, time windows may not be accurate or practical to use as they do not consider the amount of drug dispensed each time. This is notable especially in countries where drugs may be purchased for treatment of ≥3 months such as in Nordic countries. The longer time windows may lead to biased estimates of drug use duration as noticed in previous studies that longer time windows increase the risk of false-positive classifications.[@b4-clep-8-363] PRE2DUP is modifiable in many ways, and it can also be adjusted for different dispensing regulations and practices such that drugs are dispensed for 1 month only instead of 3 months as in Nordic countries.

Strengths and limitations
-------------------------

The strength of the present study was comparison of register-based data to interview that included population-based sample of older persons, and their drug use was thoroughly assessed. Interview with prescription forms, drug packages, and medical records minimizes recall bias. The Prescription register data cover all community-dwelling residents of Finland. The register does not include drugs used in hospitals, but it includes drugs that have been prescribed by hospital physicians for the continuation of treatment at home. Hospitals are not allowed to dispense drugs for discharged patients, and patients may get drugs from hospital only for one night or for a short period of time when pharmacies are closed (such as public holidays). However, interviews were not conducted during public holidays, and hence, it is believed that this would not have a major impact on our results.

PRE2DUP was applied to register data with restriction parameters developed for the MEDALZ study including community dwelling older persons of similar age and drug use patterns.[@b24-clep-8-363]--[@b26-clep-8-363] Limitations are related to limitations of the Prescription register data including only reimbursed drugs. Register-based data do not indicate whether drugs are intended for regular or "as needed" by the prescriber. It is also possible that participants might be prepared for the interview or interview encouraged them to purchase drugs more regularly, and hence, the agreement results may be better than in real life without an interview event. As the major change in drug reimbursement system impacting the inclusion of drugs in the Prescription register data happened before the chosen annual interview was conducted, the results are applicable to the current situation. However, the changing reimbursement status of specific drugs or drug products should always be considered while using register-based data.

Conclusion
==========

PRE2DUP modeling resulted in highly reliable estimates of current drug use for most of the studied drugs. The agreement was higher for drugs used continuously and lower for "as needed" use and for also drugs available OTC. PRE2DUP modeling of register data showed similar or higher agreement compared with previous studies based on fixed time windows. Modeled register data can be used instead of interview data for most drug classes as reliable source of current drug use.
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![Comparison of whether PRE2DUP modeled drug use periods were ongoing during the drug use assessment period which was 2 weeks preceding the interview date for each participant.\
**Note:** Green bars indicate drug use periods defined as "used" at the interview and blue bars as "not used."](clep-8-363Fig1){#f1-clep-8-363}

![Formation of the included drug groups (ATC classes) in the study.\
**Notes:** A06A, drugs for constipation; A12A, calcium; B03A, iron preparations; M02A, topical products for joint and muscular pain; A12B, potassium; S01X, other ophthalmologicals; D07A, dermal corticosteroids; H02A, corticosteroids for systemic use; J01E, sulfonamides and trimethoprim; J01X, other antibacterials; N04B, dopaminergic agents; R03D, other systemic drugs for obstructive airway diseases; G03C, estrogens; R06A, antihistamines for systemic use.\
**Abbreviations:** ATC, Anatomical Therapeutic Chemical; OTC, over the counter.](clep-8-363Fig2){#f2-clep-8-363}

###### 

Characteristics of study participants (N=569) in 2006 interview

  Age, mean (SD) (years)                                            82.4 (4.3)
  ----------------------------------------------------------------- ------------
  Females, % (N)                                                    69% (391)
  Intervention group, % (N)                                         52% (295)
  **Functional status**                                             
  Frailty status, % (N)[a](#tfn1-clep-8-363){ref-type="table-fn"}   
   Robust                                                           36% (195)
   Pre-frail                                                        49% (263)
   Frail                                                            15% (81)
  IADL score, mean (SD)                                             6.0 (2.3)
  MMSE score, mean (SD)                                             25.7 (5.4)
  **Comorbidities**                                                 
  FCI, mean (SD)                                                    2.9 (1.7)
  Cardiovascular disease, % (N)                                     87% (492)
  Diabetes, % (N)                                                   20% (115)
  History of stroke, % (N)                                          15% (85)
  Dementia                                                          17% (274)
  **Drug use**                                                      
  Mean number of regular drugs (SD)                                 5.8 (3.0)
  Excessive polypharmacy (≥10 drugs), % (N)                         28% (161)

**Note:**

Missing data for 30 persons.

**Abbreviations:** FCI, functional comorbidity index; IADL, instrumental activities of daily living; MMSE, Mini-Mental State Examination; SD, standard deviation.

###### 

Person-level agreement between self-report in interview and drug use calculated from prescription register data with PRE2DUP modeling method in the GeMS Study

  Drug class or drug name and ATC code                             Interview as a standard   Register as standard   Kappa (95% CI)                
  ---------------------------------------------------------------- ------------------------- ---------------------- ---------------- ----- ------ -------------------
  **Alimentary tract and metabolism**                                                                                                             
  Proton pump inhibitors, A02BC                                    50                        40                     80%              50    80%    0.78 (0.69--0.87)
  Antidiabetics, A10                                               63                        61                     97%              61    100%   0.98 (0.96--1.00)
  Insulins, A10A                                                   18                        18                     100%             18    100%   1.00 (1.00--1.00)
  Oral antidiabetics, A10B                                         55                        52                     95%              52    100%   0.97 (0.93--1.00)
  **Blood and blood forming organs**                                                                                                              
  Antithrombotic drugs, B01A                                       154                       143                    93%              149   96%    0.92 (0.89--0.96)
  **Cardiovascular system**                                                                                                                       
  Digitalis, C01A                                                  37                        35                     95%              38    92%    0.93 (0.87--0.99)
  Organic nitrates, C01DA                                          240                       195                    81%              199   98%    0.82 (0.77--0.87)
  Diuretics, C03                                                   196                       182                    93%              196   93%    0.89 (0.85--0.93)
  Beta-blocking agents, C07                                        353                       342                    97%              350   98%    0.93 (0.90--0.96)
  Calcium channel blockers, C08                                    164                       153                    93%              169   91%    0.89 (0.84--0.93)
  Agents acting on the renin- angiotensin system, C09              227                       223                    98%              240   93%    0.92 (0.89--0.96)
  Lipid-modifying agents, C10                                      214                       204                    95%              208   98%    0.95 (0.92--0.98)
  **Genitourinary system and sex hormones**                                                                                                       
  Drugs for urinary incontinence, G04BD                            20                        15                     75%              17    88%    0.81 (0.66--0.95)
  Drugs for benign prostatic hypertrophy, G04C                     47                        46                     98%              50    92%    0.94 (0.90--0.99)
  **Systemic hormonal preparations**                                                                                                              
  Levothyroxine, H03AA01                                           60                        56                     93%              56    100%   0.96 (0.92--1.00)
  **Musculoskeletal system**                                                                                                                      
  NSAIDs, M01A                                                     95                        40                     42%              64    63%    0.43 (0.32--0.53)
  Allopurinol, M04AA01                                             34                        30                     88%              32    94%    0.90 (0.83--0.98)
  Drugs for treatment of bone diseases/bisphosphonates, M05        62                        57                     92%              63    91%    0.90 (0.84--0.96)
  **Nervous system**                                                                                                                              
  Opioids, N02A                                                    16                        9                      56%              10    90%    0.69 (0.48--0.89)
  Paracetamol, N02BE01                                             214                       30                     14%              36    83%    0.15 (0.10--0.21)
  Antipsychotics, N05A                                             34                        30                     88%              32    94%    0.90 (0.83--0.98)
  Benzodiazepines and related drugs, N05BA, N05CD, N05CF           189                       134                    71%              150   89%    0.70 (0.64--0.77)
  Antidepressants, N06A                                            70                        53                     76%              57    93%    0.81 (0.74--0.89)
  Antidementia drugs, N06D                                         65                        59                     91%              59    100%   0.95 (0.90--0.99)
  **Respiratory system**                                                                                                                          
  Drugs for obstructive airway diseases, R03                       68                        55                     81%              61    90%    0.83 (0.76--0.91)
  Adrenergics, inhalations, R03A                                   55                        35                     64%              41    85%    0.71 (0.60--0.82)
  Other drugs for obstructive airway diseases, inhalations, R03B   39                        33                     85%              37    89%    0.86 (0.77--0.95)
  **Sensory organs**                                                                                                                              
  Antiglaucoma preparations, S01E                                  44                        43                     98%              50    86%    0.91 (0.84--0.97)

**Abbreviations:** ATC, Anatomical Therapeutic Chemical; CI, confidence interval; NSAIDs, non-steroidal anti-inflammatory drugs.

###### 

Person-level agreement between drugs self-reported being used on regular bases in the interview and drug use calculated from prescription register data with PRE2DUP modeling method in the GeMS Study

  Drug class or drug name and ATC code                             Interview as a standard   Register as standard   Kappa (95% CI)                
  ---------------------------------------------------------------- ------------------------- ---------------------- ---------------- ----- ------ -------------------
  **Alimentary tract and metabolism**                                                                                                             
  Proton pump inhibitors, A02BC                                    40                        34                     85%              50    68%    0.74 (0.63--0.84)
  Antidiabetics, A10                                               63                        61                     97%              61    100%   0.98 (0.96--1.00)
  Insulins, A10A                                                   18                        18                     100%             18    100%   1.00 (1.00--1.00)
  Oral antidiabetics, A10B                                         55                        52                     95%              52    100%   0.97 (0.93--1.00)
  **Blood and blood forming organs**                                                                                                              
  Antithrombotic drugs, B01A                                       154                       143                    93%              149   96%    0.92 (0.89--0.96)
  **Cardiovascular system**                                                                                                                       
  Digitalis, C01A                                                  37                        35                     95%              38    92%    0.93 (0.87--0.99)
  Organic nitrates, C01DA                                          176                       174                    99%              199   87%    0.89 (0.85--0.93)
  Diuretics, C03                                                   195                       182                    93%              196   93%    0.90 (0.86--0.93)
  Beta-blocking agents, C07                                        349                       340                    97%              350   97%    0.93 (0.90--0.96)
  Calcium channel blockers, C08                                    162                       153                    94%              169   91%    0.89 (0.85--0.93)
  Agents acting on the renin- angiotensin system, C09              227                       223                    98%              240   93%    0.93 (0.89--0.96)
  Lipid-modifying agents, C10                                      214                       204                    95%              208   98%    0.95 (0.92--0.98)
  **Genitourinary system and sex hormones**                                                                                                       
  Drugs for urinary incontinence, G04BD                            19                        15                     79%              17    88%    0.83 (0.69--0.96)
  Drugs for benign prostatic hypertrophy, G04C                     47                        46                     98%              50    92%    0.94 (0.90--0.99)
  **Systemic hormonal preparations**                                                                                                              
  Levothyroxine, H03AA01                                           60                        56                     93%              56    100%   0.96 (0.92--1.00)
  **Musculoskeletal system**                                                                                                                      
  NSAIDs, M01A                                                     21                        17                     81%              64    27%    0.37 (0.23--0.50)
  Allopurinol, M04AA01                                             31                        30                     97%              32    94%    0.95 (0.89--1.00)
  Drugs for treatment of bone diseases/bisphosphonates, M05        62                        57                     92%              63    91%    0.90 (0.84--0.96)
  **Nervous system**                                                                                                                              
  Opioids, N02A                                                    4                         4                      100%             10    40%    0.57 (0.26--0.88)
  Paracetamol, N02BE01                                             50                        13                     25%              36    36%    0.25 (0.12--0.38)
  Antipsychotics, N05A                                             33                        30                     91%              32    94%    0.92 (0.85--0.99)
  Benzodiazepines and related drugs, N05BA, N05CD, N05CF           106                       94                     89%              150   63%    0.66 (0.59--0.73)
  Antidepressants, N06A                                            68                        53                     78%              57    93%    0.83 (0.76--0.90)
  Antidementia drugs, N06D                                         65                        59                     91%              59    100%   0.95 (0.90--0.99)
  **Respiratory system**                                                                                                                          
  Drugs for obstructive airway diseases, R03                       54                        49                     91%              61    80%    0.84 (0.76--0.91)
  Adrenergics, inhalations, R03A                                   29                        25                     86%              41    61%    0.70 (0.57--0.82)
  Other drugs for obstructive airway diseases, inhalations, R03B   35                        31                     89%              37    84%    0.85 (0.76--0.94)
  **Sensory organs**                                                                                                                              
  Antiglaucoma preparations, S01E                                  44                        43                     98%              50    86%    0.91 (0.84--0.97)

**Note:** "As needed" drugs according to interview are not included.

**Abbreviations:** ATC, Anatomical Therapeutic Chemical; CI, confidence interval; NSAIDs, non-steroidal anti-inflammatory drugs.

[^1]: These authors contributed equally to this work.
